Heparin-Binding EGF-Like Growth Factor (HB-EGF) Overexpression Is Associated with Aggressive Disease in Endometrial Carcinoma
J Torres-Mora, CE Sheehan, JS Ross. Albany Medical College, Albany, NY
Background: HB-EGF is a cell proliferation associated growth factor which is also known to stimulate angiogenesis. Although linked to adverse disease outcome in several tumors, HB-EGF expression in endometrial cancer has not been previously studied as a potential clinically useful biomarker for endometrial carcinoma.
Design: Formalin-fixed, paraffin-embedded tissue sections from 126 endometrial carcinomas, including 102 endometrioid carcinoma (EC), 12 uterine papillary serous carcinoma (PSC) and 12 malignant mesoderm mixed tumor (MMMT) were immunostained by automated methods (Ventana Medical Systems Inc., Tucson, AZ) using mouse monoclonal HB-EGF (Abcam, Cambridge, MA). Cytoplasmic immunoreactivity was semiquantitatively scored based on staining intensity and distribution and the results were correlated with morphologic and prognostic variables.
Results: Cytoplasmic HB-EGF overexpression was observed in 66/126 (52%) tumors, including 53/102 (52%) EC, 8/12 (67%) PSC, and 5/12 (42%) MMMTs. HB-EGF overexpression correlated with tumor grade (61% grade 3 vs. 59% grade 2 vs. 31% grade 1, p=0.035), advanced tumor stage (74% stage III/IV vs. 45% stage I/II, p=0.007), depth of myometrial invasion (74% invading to more than 50% of myometrium vs. 47% to less than 50% vs. 40% no invasion, p=0.023). A trend for correlation with disease recurrence was noted overall [70% recurrent vs 49% non-recurrent, p=0.079] and within the PSC subgroup [100% recurrent vs 50% non-recurrent, p=0.083]. There was no correlation with overall survival.
Conclusions: HB-EGF expression is associated with aggressive forms of endometrial carcinoma and significantly correlates with tumor grade and pathologic stage and may be a predictor of overall disease recurrence after primary treatment. Continued study of this biomarker in endometrial malignancies appears warranted.
Category: Gynecologic & Obstetrics
Wednesday, March 24, 2010 9:30 AM
Poster Session V # 136, Wednesday Morning